Zydus Pharmaceuticals recalled 4,344 bottles of Entecavir Tablets on September 4, 2025. The recall stems from failed impurity and degradation specifications. Consumers should stop using the product immediately.
Failed Impurity/Degradation Specifications
Consumers and healthcare providers should stop using this product immediately. Contact Zydus Pharmaceuticals (USA) Inc or your healthcare provider for guidance. Notification method: N/A
The recalled product is Entecavir Tablets, USP, 0.5 mg, packaged in bottles of 30 tablets. The affected lot number is E309376, with an expiration date of November 30, 2025. These tablets were distributed nationwide across the United States.
The recall is classified as Class II due to failed impurity and degradation specifications. This means the product may cause temporary or medically reversible adverse health consequences.
There have been no reported injuries or incidents associated with the use of these tablets at this time.
Consumers and healthcare providers should stop using Entecavir Tablets immediately. For guidance, contact Zydus Pharmaceuticals (USA) Inc. or consult a healthcare provider.
For more information, call Zydus Pharmaceuticals at 1-800-XXX-XXXX or visit their website at www.zydususa.com.
Glenmark Pharmaceuticals Inc. recalled 13,824 tubes of Azelaic Acid Gel on September 17, 2025. The recall stems from market complaints regarding a gritty texture. Consumers should stop using the product immediately and contact their healthcare provider.
Skin MD by Dr Monika Kiripolsky recalled its Body Acne Cleanser on September 12, 2025. The recall follows the discovery of elevated benzene levels in the product. This contamination poses a high health risk to consumers in California and Georgia.
Private Label Skin Care recalled its Micronized BPO Gel Cleanser 10% on September 12, 2025. Elevated benzene levels prompted the recall in California and Georgia. Consumers must stop using the product immediately and seek guidance from healthcare providers.